Dr. Milad Alucozai, an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor, is dedicated to leveraging his expertise in bioengineering, computational biology, and machine learning to revolutionize translational research and development. His ultimate goal is to significantly enhance patient care and fundamentally transform the field of medicine. His unwavering commitment to commercializing groundbreaking technologies and nurturing thriving startup ecosystems globally has earned him a reputation as a highly respected thought leader and dedicated mentor for entrepreneurs through the Creative Destruction Lab and the Wyss Institute at Harvard University.
Dr. Alucozai is a co-founder at Revalia Bio, a startup developing AI-powered digital twins of living human organs by utilizing donated organs for research. This approach provides an unprecedented level of human data with direct clinical relevance. He also holds the position of Senior Advisor at 16 Tech Innovation District and co-hosts the newly launched Code to Cure Series with the Wyss Institute at Harvard University.
Previously, as Head of Bio and Deep Tech at BoxOne Ventures, he spearheaded 70 early-stage investments, establishing the firm as a leading player in North America’s venture capital landscape. He also served as a Venture Partner at Entrepreneur First, a globally recognized talent investor backed by notable figures like Patrick and John Collison of Stripe and Reid Hoffman of LinkedIn, with a portfolio exceeding $10 billion in value.
Throughout his operating and investor career, Dr. Alucozai has supported nearly $1 billion in startup partnerships with pharmaceutical companies. He has also been instrumental in helping his founders secure hundreds of millions in capital, enabling them to scale their companies successfully. Often serving as their first investor, he provides guidance throughout their entrepreneurial journey, from the initial idea to a successful exit.
In addition to his investment and advisory roles, Dr. Alucozai is a Fellow in Healthcare Engineering at the Regenstrief Center and has served as an External Advisor to AstraZeneca. A Phi Beta Kappa graduate with a degree in Neuroscience from Purdue University’s Honors Program, he furthered his studies as a George J. Mitchell Scholar, completing a master’s in Immunology at the National University of Ireland and earning his doctorate from the Richard M. Fairbanks School of Public Health.
At the Wyss Institute, Milad is a member of the Wyss Mentor Hive who specializes in commercializing transformative technologies and fostering startup ecosystems.
The Wyss Mentor Hive is a mentoring program that invites investors and business professionals with significant early stage translational experience, clinical and regulatory experts in driving therapeutic and device development, and serial entrepreneurs with a track record of success to work closely with Wyss entrepreneur teams on startup formation and technology commercialization. Mentors provide feedback to founders and entrepreneurs, while also demonstrating commitment and leadership in the Wyss innovation community.